ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 GACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial FibrillationCYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuideliThoracic aortic aneurysm and dissection2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesDevice-detected atrial fibrillation: what to do with asymptomatic patients?Patent foramen ovale and recurrent stroke: another paradoxical twistLessons from the Stroke Prevention in Atrial Fibrillation trialsRisks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trialsAnticoagulation for atrial fibrillation in the elderlyAntithrombotic therapy in atrial fibrillation: the Seventh ACCP Conference on Antithrombotic and Thrombolytic TherapyConfronting atrial fibrillation in the elderly: stroke risk stratification and emerging antithrombotic therapiesLimitation of the resting ankle-brachial index in symptomatic patients with peripheral arterial diseaseACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non–ST-Elevation Myocardial Infarction2011 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines for theGuidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke associationACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update 2001 Guidelines for PercGuidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke...2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on Dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial FibrillationDronedarone in High-Risk Permanent Atrial FibrillationACC/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (WritiCause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AFACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 GuiThrombocytopenia during heparin therapy: a clinical conundrum.Use and outcomes of antiarrhythmic therapy in patients with atrial fibrillation receiving oral anticoagulation: results from the ROCKET AF trial.Trials of novel oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.Relationship between time in therapeutic range and comparative treatment effect of rivaroxaban and warfarin: results from the ROCKET AF trial.2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines.Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society.Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).Outcomes in atrial fibrillation patients with and without left ventricular hypertrophy when treated with a lenient rate-control or rhythm-control strategy.
P50
Q22306349-FF80116E-E67F-4189-8C75-3145FB27DCA4Q22306351-975FBC11-F769-46A9-8986-6401D1C0A93CQ24641999-8F3DC7CE-8E33-41B7-B0CF-D386A4D82E25Q26853613-AAB7D8AC-4C28-49D5-B6BA-5FC66B651162Q27000110-B57131A0-FCC1-477B-804C-793A3A9676D1Q27010140-62DE0AC8-E43F-49A7-8D1F-132D0CB1909DQ28087510-7182B187-81B7-4A5D-92CE-2C08C270977FQ28193123-33606E94-DA37-4F81-8199-E5E153FCED5BQ28196151-94276A73-A49E-433A-A577-D6B4DA72A755Q28201304-FDDC76F6-8180-44F1-A80E-7B53D72D8AB2Q28211244-8B34EBEC-6D91-4570-BDD7-5388D1557706Q28213401-336BDCA4-0CAD-4F89-BFE2-87929476FEE7Q28220306-4B0B2DF6-DC18-43DC-9F0F-032F061286FCQ28237887-A9D9690F-D85E-4772-AA93-87DD9A58A80FQ28240355-0098FF1E-6419-4439-8FAC-013355D31972Q28249469-32D9B9DA-2CD7-4A74-9845-E1F605F6FDEBQ28255148-B9E09FC1-E5E6-460F-A8D5-41A26FAE00B4Q28296349-D8C182D1-1E69-402E-8868-D37F432B6E94Q28298419-977574EE-78B2-4A6E-8154-E3951E9B65FFQ28301737-165319E1-2201-4F1E-BD7D-567BF5D95F1FQ28301815-ADE4158D-6BC9-4700-B57C-A6610104F11EQ28305368-EBEC1A5B-D9E7-48FD-BFAE-B9F7A7140221Q28307011-F0FCE157-CCDE-47B3-BA5C-CE6DCF835D50Q29397457-998F1C2E-4310-45D1-B433-2ED4FC581FB3Q30940275-2516A62E-5B0E-430E-B90E-B1EB5BCC01F3Q31054764-3244E9A8-CAC6-45D7-B525-23CC3BE563D4Q33156283-E1F9689A-7BAD-400D-80B6-B40B4A97422FQ33380008-199F2861-FD79-4CBE-9EB0-B53D00AFFDF9Q33671190-FE363215-8FE2-4BFB-902A-FCBEC08C566BQ33911981-0C0B2A55-CD29-4481-9F51-7A2FD628C1C6Q34152050-E4432334-8F90-4BC5-AD8E-FCB0F2FAAF56Q34154032-38C57571-A271-4C1F-AB8E-D63E4BB26075Q34196283-6EDAA63D-E611-42C3-B35E-AF413B05B1DBQ34297266-A2F598EF-58BC-4D1C-921C-A2536B2FA77AQ34318814-52DEC91A-DA47-4FC2-B3DD-0D2F40FD04B1Q34336306-A6D1D985-3758-4184-9C46-99FCF3C85432Q34344580-17E96A5F-3A61-41CE-A628-94673CCE4EE6Q34384547-4853F759-F10D-4DCE-AAE6-E77474996672Q34388959-8DF716C4-F5A1-461B-9DC6-3C43179E8243Q34403091-4C7490C3-EBCC-49E3-A66E-EFF69D51D94E
P50
description
American cardiologist
@en
cairdeolaí Meiriceánach
@ga
cardiolojiste american
@lfn
cardiólogu estauxunidense
@ast
usona kardiologo
@eo
name
Jonathan L. Halperin
@ast
Jonathan L. Halperin
@ca
Jonathan L. Halperin
@en
Jonathan L. Halperin
@es
Jonathan L. Halperin
@fr
Jonathan L. Halperin
@ga
Jonathan L. Halperin
@nl
Jonathan L. Halperin
@sl
جاناتان ال. هالپرین
@azb
جوناثان إل. هالبرين
@ar
type
label
Jonathan L. Halperin
@ast
Jonathan L. Halperin
@ca
Jonathan L. Halperin
@en
Jonathan L. Halperin
@es
Jonathan L. Halperin
@fr
Jonathan L. Halperin
@ga
Jonathan L. Halperin
@nl
Jonathan L. Halperin
@sl
جاناتان ال. هالپرین
@azb
جوناثان إل. هالبرين
@ar
prefLabel
Jonathan L. Halperin
@ast
Jonathan L. Halperin
@ca
Jonathan L. Halperin
@en
Jonathan L. Halperin
@es
Jonathan L. Halperin
@fr
Jonathan L. Halperin
@ga
Jonathan L. Halperin
@nl
Jonathan L. Halperin
@sl
جاناتان ال. هالپرین
@azb
جوناثان إل. هالبرين
@ar
P214
P244
P106
P19
P21
P213
0000 0000 6735 9406
P214
P244
P31
P569
1949-01-29T00:00:00Z
P691
mub20181010507
P735
P7859
lccn-n84224734